Trials / Completed
CompletedNCT05844956
A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1)
A Phase 1/2, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Dizal Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the safety, tolerability, pharmacokinetic profile, and antitumor efficacy of DZD8586 in participants with relapsed or refractory B-NHL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DZD8586 | Daily dose of DZD8586, except for cycle 0 of Part A, in which a single dose of DZD8586 is administrated. Starting dose of DZD8586 is 10 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD8586. |
Timeline
- Start date
- 2022-06-01
- Primary completion
- 2024-02-29
- Completion
- 2024-02-29
- First posted
- 2023-05-06
- Last updated
- 2025-02-21
Locations
6 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05844956. Inclusion in this directory is not an endorsement.